Parthiban SK

343 PQTWiST analysis to compare the benefit of metronomic chemotherapy versus intravenous cisplatin for patients with head and neck cancer - 2017 -

Background: In an open label, Phase 2 randomised study, metronomic chemotherapy was found to be superior to intravenous cisplatin in terms of progression free survival in patients with Head and neck cancer. In this analysis we will assess the benefit of metronomic over intravenous cisplatin using quality adjusted time without symptom or toxicity analysis method.

Methods: The overall survival in each arm will be partitioned into 3 health states. TOX state (Time spent in grade 3 or above toxicity after randomization and before progression), TWiST state (Time spent after randomization before progression without grade 3 or above toxicity) and REL state (Time spent after progression). The mean QTWiST was calculated for each arm using threshold utility analysis. The difference in QTWiST and the 95% CI of difference...


Head and neck cancer
Chemotherapy
Cisplatin
Metronomic

Powered by Koha